Certara, Inc. (CERT): Results of Operations and Financial Condition
Certara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 q22026earningsreleaseex99.htm EX-99 Document Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million
How this was made
The 30-second read
Why it matters
The 8-K updates continuing-operations financials, highlights segment performance (software up, services down), and reiterates the full-year revenue growth band while detailing cost actions and leadership changes.
Market read
Traders can update positioning based on Q2 segment trends, bookings, and the reaffirmed FY revenue growth range, plus the expected $13M run-rate savings from the reorganization.
What to watch
Services bookings declined (down 6% YoY) even as software bookings rose (up 9%); investors may re-rate the mix and near-term cash generation if services weakness persists.
Background
Certara is reorganizing around two business units (MID3 and ACE) after divesting its Regulatory and Medical Writing business in May 2026.
Ticker impact
Certara reported Q2 2026 continuing-ops revenue of $93.3M, net loss of $6.1M, and reaffirmed full-year revenue growth of 0% to 4%.
Near-term trading likely modest, with focus on whether software bookings strength persists and whether cost savings from the reorganization offset margin pressure.
The filing provides concrete quarterly datapoints (revenue, segment revenue, net loss, adjusted EBITDA) plus a reaffirmed full-year range, but it does not introduce a surprise guidance change or a discrete one-off event beyond accounting and restructuring items.
Market effects
Signals ongoing demand resilience in software for model-informed drug development, while services remain under pressure.
No specific regional impact disclosed beyond company-wide restructuring and cost actions.
Limited; the disclosure is company-specific with no stated macro or regulatory shock.
Counterpoint
Net loss widened largely due to contingent consideration remeasurement and reorganization-related costs, so headline profitability may not reflect underlying operating momentum.
Key entities
- companyCertara, Inc.
Nasdaq-listed model-informed drug development company reporting Q2 2026 continuing-ops results and reaffirming FY revenue guidance.
- executiveJulien Perrier
Appointed Chief Commercial Officer effective Aug 1, 2026, to lead unified commercial execution.
- executiveEric Jahn
Appointed Chief Information Officer, previously Senior Vice President, IT.
